reports
InFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code
InFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code PLA Code issuance by the American Medical Association CPT editorial panel marks a meaningful step toward attaining health insurance reimbursement and expanded patient access for inFoods® IBSinFoods® IBS provides personalized identification of food triggers to substantially improve IBS-related symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company focused on innovative gastroenterology diagnostics, to...
Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Tea...
Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer Brings 20+ years of revenue growth leadership in laboratory testing, clinical diagnostics and global expansionLed successful organizational turnarounds and growth strategies at both Boston Heart Diagnostics and Genova DiagnosticsExtensive track record in commercializing advanced laboratory testing, driving growth and payer strategies IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology so...
Biomerica Appoints Eric B. Chin to Board of Directors and Audit Commit...
Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair Mr. Chin brings over 20 years of financial experience across public and private healthcare organizationsMr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financingMr. Chin’s appointment strengthens Biomerica’s corporate governance and financial oversight as Biomerica scales commercialization efforts IRVINE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company that develops, patents, manufactures and mark...
Biomerica’s inFoods® IBS Clinical Study Results Published in June Issu...
Biomerica’s inFoods® IBS Clinical Study Results Published in June Issue of Gastroenterology Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Patients Using inFoods® IBS Test.Gastroenterology, the premier journal in gastrointestinal science, features data supporting inFoods IBS as an effective personalized, non-drug approach for managing IBS.Study results suggest inFoods IBS could be particularly beneficial for IBS-M patients, a population with no current FDA-approved drug treatments. IRVINE, Calif., June 05, 2025 (GLO...
Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptom...
Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period First-of-Its-Kind inFoods® IBS Feedback Platform: New real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomesPrecision Medicine: inFoods® IBS identifies specific individual food triggers...
PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Re...
PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement - Application represents milestone toward broadening patient access to inFoods IBS - inFoods® IBS pinpoints patient-specific foods that can trigger IBS symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif. , May 07, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company dedicated to the development of advanced diagnostic products, announced that the Company and its CLIA laboratory partner have submitted an application to the ...
United Arab Emirates Ministry of Health and Prevention Approves Biomer...
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Detection of H. pylori Infection 10-minute test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerApproximately 80% of gastric cancer cases are linked to H. pylori infection; WHO classifies H. pylori as a Class 1 carcinogenThis test empowers healthcare providers with fast, accessible testing across the UAE IRVINE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solution...
United Arab Emirates Ministry of Health and Prevention Approves Biomer...
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Disease Test for Early Detection of Kidney Damage Regulatory milestone enables commercial expansion into high-need international market10-minute test detects early signs of kidney damage using a simple urine sample Addresses global public health burden of Chronic Kidney Disease (CKD), with high relevance in the UAE IRVINE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that its Fortel® Kidney Disease (...
Biomerica Announces Reverse Stock Split
Biomerica Announces Reverse Stock Split Shares Expected to Begin Trading on Split-Adjusted Basis on April 21, 2025 IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, today announced that it will implement a 1-for-8 reverse stock split of the issued and outstanding shares of its common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern time on April 21, 2025. Biomerica’s common stock is expected to begin trading on a split-adjusted basis when the market opens on Monday, April 21,...
Biomerica Reports Third Quarter Fiscal 2025 Financial Results
Biomerica Reports Third Quarter Fiscal 2025 Financial Results Total Revenue Increases 10% Year-Over-YearDelivers Improved Gross Margins, Achieves Annual Cost Savings Target Early, and Reduces Cash Burn Over 55% IRVINE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2025 ended February 28, 2025. Key Highlights: 1. Fortel® PSA Screening Test Approved by UAE Ministry of Health & Prevention:Biomerica’s Fortel®...
Biomerica Achieves IVDR Certification in the European Union for Food I...
Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis Significant Milestone: Biomerica secures IVDR (In Vitro Diagnostic Regulation) certification, ensuring compliance with stringent European Union standards and allowing sales of the products in the EUFocus on Precision Medicine: Certification covers Biomerica’s food intolerance products developed to support patients with Crohn’s Disease and Ulcerative Colitis (UC), both of which are chronic and debilitating inflammatory bowel diseases (IBD).Global Reach: Posi...
Biomerica’s inFoods® IBS Clinical Trial Results Published and Featured...
Biomerica’s inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal inFoods IBS Provides Personalized Diet Therapy for Patients Suffering with Irritable Bowel Syndrome (IBS)Research Finds Patients Following a Personalized Diet Therapy Created with inFoods® IBS, Experienced Reduced Abdominal Pain and Bloating IRVINE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced medical diagnostic solutions, is proud to announce that patients with Irritable Bowel Syndrome (IBS) may experience si...
United Arab Emirates Ministry of Health and Prevention Approves Biomer...
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer - 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer - Prostate Cancer: The Second Most Common Cancer in Men Globally IRVINE, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of innovative diagnostic solutions, is proud to announce that its Fortel® Prostate Specific Antigen (PSA) Screening Test has received approval from the United Arab ...
Biomerica Reports Second Quarter Fiscal 2025 Financial Results
Biomerica Reports Second Quarter Fiscal 2025 Financial Results - Total Revenue Increases 5% Year-Over-Year - Achieves Sustained Revenue Growth, Improved Gross Margins, and Significant Cost Savings IRVINE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2025 ended November 30, 2024. Key Highlights: Direct-to-Consumer Launch of i...
Biomerica Secures Three Key International Patents for inFoods® Technol...
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The company received three notices of allowance in countries within the European Patent Organization (EPO), including Germany, UK, France, Italy, Spain, and over 30 additional nations within the European Patent Treaty IRVINE, Calif., Nov. 21, 2024 (GLOBE NEWSWIR...
Nasdaq grants Biomerica an additional 180 days to meet listing complia...
Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Market LLC ("Nasdaq") to meet the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market. This extension allows Biomerica until May 5, 2025, to regain compliance. This extension was provided because Biomerica currently meets th...
Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Te...
Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain Patients experiencing bloating and gastrointestinal discomfort can now order inFoods® IBS directly from without needing to visit a doctor’s officeWith a simple, at-home finger-prick blood sample, patients can receive a personalized test result identifying potential IBS trigger foods The inFoods® IBS test empowers patients with actionable results to reduce bloating and gastrointestinal pain IRVINE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. ...
Biomerica Reports First Quarter Fiscal 2025 Financial Results
Biomerica Reports First Quarter Fiscal 2025 Financial Results Total Revenue Increases 6% Over Same Period Last Year Cost-Saving Measures Now Implemented, Expected to Reduce Annual Expenses by 16% to 23%, Representing $1.0 to $1.4 Million ReductionBiomerica's At-Home PSA Screening Test Receives Saudi Food and Drug Authority (SFDA) Approval for Early Detection of Prostate Cancer IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reporte...
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home ...
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer - 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) is pleased to announce that the Saudi Food and Drug Authority (SFDA) has approved the Company's Fortel® Prostate (PSA) Screening Test to be sold and used in the country. This at-home test...
Biomerica Reports Fiscal 2024 Year End Results
Biomerica Reports Fiscal 2024 Year End Results Total Revenue Increases 1% Year-Over-Year – Core Revenue Excluding COVID Tests Climbs 5%, Reflecting Stronger GrowthSignificant Cost Savings Plan Implemented After Year End – Expected to Deliver Expense Reductions of $1.0 to $1.4 Million in the Coming YearinFoods® IBS Pilot with Large 1,100 Physician Group Progressing Ahead of Schedule IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2024. The Company achieved a modest increase in net sales...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.